PATHUiPath, Inc.

NYSE uipath.com


$ 19.76 $ 0.30 (1.54 %)    

Monday, 29-Apr-2024 15:59:54 EDT
QQQ $ 433.04 $ 1.75 (0.41 %)
DIA $ 383.81 $ 1.49 (0.39 %)
SPY $ 510.06 $ 1.80 (0.35 %)
TLT $ 88.99 $ 0.74 (0.84 %)
GLD $ 216.18 $ -0.44 (-0.2 %)
$ 19.76
$ 19.74
$ 0.00 x 0
$ 0.00 x 0
$ 19.59 - $ 19.96
$ 12.38 - $ 27.87
4,741,496
na
11.14B
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-27-2024 01-31-2024 10-K
2 12-04-2023 10-31-2023 10-Q
3 09-07-2023 07-31-2023 10-Q
4 06-02-2023 04-30-2023 10-Q
5 03-24-2023 01-31-2023 10-K
6 12-05-2022 10-31-2022 10-Q
7 09-08-2022 07-31-2022 10-Q
8 06-03-2022 04-30-2022 10-Q
9 04-04-2022 01-31-2022 10-K
10 12-10-2021 10-31-2021 10-Q
11 09-08-2021 07-31-2021 10-Q
12 06-09-2021 04-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cathie-woods-ark-empire-bleeds-as-investor-outflows-spike-the-loyal-shareholders-have-become-frustrated

In early 2021, Cathie Wood's ARK Invest managed $59B across 6 funds, becoming the world's largest active ETF manager. H...

 cathie-woods-ark-invest-continues-to-shed-coinbase-nvidia-shares

On Monday, Cathie Wood-led Ark Invest made significant trades involving Coinbase Global Inc. (NASDAQ:COIN) and NVIDIA Corp. (NA...

 cathie-woods-ark-invest-sells-20m-coinbase-shares-as-bitcoin-trades-over-70k-buys-palantir-sells-nvidia-stock

On Thursday, Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc. (NASDAQ:COIN), Palantir Technolog...

 expert-ratings-for-uipath
Expert Ratings For UiPath
04/08/2024 13:00:34

 keybanc-assumes-uipath-at-overweight-announces-price-target-of-27

Keybanc analyst Jason Celino assumes UiPath (NYSE:PATH) with a Overweight rating and announces Price Target of $27.

 rbc-capital-reiterates-sector-perform-on-uipath-maintains-29-price-target

RBC Capital analyst Matthew Hedberg reiterates UiPath (NYSE:PATH) with a Sector Perform and maintains $29 price target.

 uipath-secures-fedramp-approval-paving-way-for-enhanced-ai-automation-in-government-services

UiPath (NYSE:PATH), a leading enterprise automation and AI software company, today announced that UiPath Automation Cloud™ Publ...

 truist-securities-reiterates-buy-on-uipath-maintains-32-price-target

Truist Securities analyst Terry Tillman reiterates UiPath (NYSE:PATH) with a Buy and maintains $32 price target.

 rbc-capital-reiterates-sector-perform-on-uipath-maintains-29-price-target

RBC Capital analyst Matthew Hedberg reiterates UiPath (NYSE:PATH) with a Sector Perform and maintains $29 price target.

 needham-reiterates-buy-on-uipath-maintains-30-price-target

Needham analyst Scott Berg reiterates UiPath (NYSE:PATH) with a Buy and maintains $30 price target.

 canaccord-genuity-maintains-buy-on-uipath-raises-price-target-to-30

Canaccord Genuity analyst Kingsley Crane maintains UiPath (NYSE:PATH) with a Buy and raises the price target from $27 to $30.

 where-uipath-stands-with-analysts
Where UiPath Stands With Analysts
03/15/2024 12:01:58

 barclays-maintains-equal-weight-on-uipath-raises-price-target-to-25

Barclays analyst Raimo Lenschow maintains UiPath (NYSE:PATH) with a Equal-Weight and raises the price target from $23 to $25.

 uipath-upgraded-by-jp-morgan-on-hope-of-stable-arr-growth-several-other-analysts-bump-up-forecasts

UiPath Inc. reports strong 4Q24 results, beating analyst estimates and seeing potential for growth in revenue and profitability...

 whats-going-on-with-uipath-stock-after-earnings

The company reported quarterly earnings of 22 cents per share which beat the analyst consensus estimate of 16 cents by 37.5%, a...

 why-limbach-holdings-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION